Analyzing Analyst Recommendations: DURECT Corporation (DRRX), Edge Therapeutics, Inc. (EDGE)

DURECT Corporation (NASDAQ:DRRX) tinted gains of +1.72% (+0.01 points) to US$0.59. The volume of 0.39 Million shares climbed down over an trading activity of 401.95 Million shares. EPS ratio determined by looking at last 12 month figures is -0.06. Over the same time span, the stock marked US$2.55 as its best level and the lowest price reached was US$0.46. The corporation has a market cap of US$99.39 Million.

DURECT Corporation (NASDAQ:DRRX)’s earnings per share has been growing at a -16.4 percent rate over the past 5 year when average revenue increase was noted as -1.5 percent. The return on equity ratio or ROE stands at -36.9 percent while most common profitability ratio return on investment (ROI) was -5.4 percent. The company’s institutional ownership is monitored at 48.7 percent. The company’s net profit margin has achieved the current level of -28.4 percent and possesses 87.7 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 1 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Edge Therapeutics, Inc. (NASDAQ:EDGE) is worth US$11.72 Million and has recently fallen -5.59% to US$0.38. The latest exchange of 0.21 Million shares is below its average trading activity of 628.74 Million shares. The day began at US$0.4 but the price moved to US$0.37 at one point during the trading and finally capitulating to a session high of US$0.4. The stock tapped a 52-week high of US$17.77 while the mean 12-month price target for the shares is US$1.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 0.38, and a price to sales ratio of 0. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown -64.8%. With an institutional ownership near 31.9%, it carries an earnings per share ratio of -2.09.